Ua hoʻolaha aku nei ʻo Ascentage Pharma ua ʻāpono ʻia kāna mea hoʻopaʻa hou Bcl-2 selective inhibitor lisaftoclax (APG-2575) e ka National Medical Products Administration (NMPA) o Kina no ka mālama ʻana i nā poʻe maʻi makua me ka maʻi leukemia lymphocytic mau/lymphoma lymphocytic liʻiliʻi (CLL/SLL) i loaʻa mua ma ka liʻiliʻi o hoʻokahi lāʻau lapaʻau systemic me nā mea hoʻopaʻa tyrosine kinase (BTK) a Bruton, ka mea e hoʻolilo ai iā lisaftoclax i ka mea hoʻopaʻa Bcl-2 mua i loaʻa ka ʻae ʻia a me ka ʻae kūʻai aku no ka mālama ʻana i nā poʻe maʻi me CLL/SLL ma Kina, a ʻo ka lua o ka mea hoʻopaʻa Bcl-2 i ʻāpono ʻia ma ka honua holoʻokoʻa.
ʻO Lisaftoclax kahi mea hoʻopaʻa koho Bcl-2 liʻiliʻi i hāʻawi ʻia ma ka waha i hoʻomohala ʻia e Ascentage Pharma e mālama i nā maʻi me nā maʻi ʻino ma ke kāohi koho ʻana i ka protein antiapoptotic Bcl-2 a no laila e hoʻihoʻi i ke kaʻina hana apoptosis maʻamau i nā cell cancer. I loko o nā hoʻokolohua lapaʻau, ua hōʻike ʻo lisaftoclax i nā hiki ke hoʻōla ākea i nā maʻi hematologic he nui a me nā puʻupuʻu paʻa, ʻoi aku hoʻi i CLL/SLL, ma ke ʻano he monotherapy a me nā hui pū ʻana.
Hoʻokumu ʻia kēia ʻae ʻia ma nā hopena mai kahi noiʻi hoʻopaʻa inoa koʻikoʻi Phase II (APG2575CC201) i hoʻolālā ʻia e loiloi i ka pono a me ka palekana o ka lisaftoclax monotherapy i nā poʻe maʻi me ka CLL/SLL i hoʻihoʻi ʻia a i ʻole refractory, me ka helu pane holoʻokoʻa (ORR) ma ke ʻano he hopena mua. Ua hōʻike ʻo Lisaftoclax i ka pono hoʻohihi a me kahi ORR i hoʻokō i ka hopena i kuhikuhi mua ʻia i nā poʻe maʻi i mālama mua ʻia me nā mea hoʻopaʻa BTK a/a i ʻole immunochemotherapy. Eia kekahi, ua hōʻike ʻo lisaftoclax i kahi ʻano palekana maikaʻi me ka ʻole o ka tumor-lysis syndrome (TLS) e hana ʻia ana i ka wā o ke aʻo ʻana, kahi haʻahaʻa o nā mea ʻawaʻawa hematologic i hiki ke hoʻokele ʻia, a me kahi haʻahaʻa o nā mea ʻawaʻawa non-hematologic i ka hapa nui o ka papa 1-2.
He maʻi ʻino koko ka CLL/SLL i hoʻokumu ʻia e nā neoplasms B-cell makua. Hoʻopilikia nui ia i nā heluna kanaka ʻelemakule me nā maʻi hou he 100,000 i hōʻike ʻia ma ka honua holoʻokoʻa i kēlā me kēia makahiki1. Ma Kina, kahi i haʻahaʻa ai ka nui o ka maʻi o CLL/SLL ma mua o nā ʻāina komohana, ke piʻi wikiwiki nei ka maʻi, me ka makahiki ʻōpio o ka hoʻomaka ʻana a me ka huhū kiʻekiʻe2. Ma ke ʻano he koho mua o kēia manawa no ka mālama mua ʻana o CLL/SLL, ua hoʻomaikaʻi nui nā mea hoʻopaʻa BTK i ka hopena lapaʻau no nā maʻi. Eia nō naʻe, ke kū nei nā mea hoʻopaʻa BTK i nā pilikia like ʻole e like me ka hiki ke hoʻoulu i nā pane hohonu, ka nui o ka pilikia o ka hoʻi hou ʻana i ka mālama waena a me ka lōʻihi, nā mea ʻawaʻawa a me ka hiki ʻole ke hoʻomanawanui e pili ana i ka mālama lōʻihi; no laila, ka pono no nā koho lapaʻau palekana a ʻoi aku ka maikaʻi no nā maʻi me CLL/SLL.
Ua hoʻololi hou ka hoʻolauna ʻana o nā mea hoʻopaʻa Bcl-2 i ka mālama ʻana iā CLL/SLL. ʻO ka mea hoʻopau apoptosis Bcl-2, i hoʻonui pinepine ʻia i nā ʻano maʻi hematologic like ʻole, ʻo CLL/SLL hoʻi, he ʻano hana nui ia e pale aku ai nā cell tumor i ka apoptosis. Eia nō naʻe, ʻo ka ʻike ʻana o ka mea hoʻopaʻa Bcl-2 ma ke ʻano he pahuhopu therapeutic he mea paʻakikī loa ia no ka mea ua hoʻokumu ʻia kāna ʻano hana ma ka pilina protein-protein (PPI). He nui ka pilina hoʻopaʻa o Bcl-2, e paʻakikī ai i nā mea hoʻopaʻa molekole liʻiliʻi ke hoʻokō i nā hopena pale. Eia kekahi, aia ka protein Bcl-2 ma ka mitochondria, me ka ʻano membrane pālua, ʻo ia kekahi o nā ʻāpana cellular paʻakikī loa no ka mea pono nā lāʻau lapaʻau e komo mua i ka membrane cell ma mua o ko lākou hana hou ʻana ma ka membrane mitochondrial. Ma mua o kēia, ʻaʻohe mea hoʻopaʻa Bcl-2 i ʻae ʻia no ka mālama ʻana iā CLL/SLL ma Kina. Hoʻopiha kēia ʻae no lisaftoclax i kahi hakahaka mālama ma CLL/SLL, e lawe mai ana i ka manaʻolana hou i nā maʻi he nui ma ka ʻāina.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
Email：myimmnet@163.com
Ka manawa hoʻouna: Iulai-15-2025